Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): An open-label, randomised controlled trial

The Lancet Infectious Diseases

Volumn 16, Issue 2, 2016, Pages 180-188

  Grigg, Matthew J ^a   William, Timothy ^a,b,e   Menon, Jayaram ^b   Dhanaraj, Prabakaran ^b   Barber, Bridget E ^a   Wilkes, Christopher S ^a   von Seidlein, Lorenz ^a,c   Rajahram, Giri S ^a,b   Pasay, Cielo ^d   McCarthy, James S ^d   Price, Ric N ^a,f   Anstey, Nicholas M ^a   Yeo, Tsin W ^a,g,h  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Sabah Department of Health   (Malaysia)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Jesselton Medical Centre   (Malaysia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^h TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; MESSENGER RNA; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; MEFLOQUINE;

ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FEVER; GAMETOCYTE; HOSPITAL BED UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTICENTER STUDY; PARASITE CLEARANCE; PLASMODIUM KNOWLESI MALARIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; MALARIA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLASMODIUM KNOWLESI; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA; MALAYSIA; MALE; MEFLOQUINE; MIDDLE AGED; PLASMODIUM KNOWLESI; YOUNG ADULT;

EID: 84957441247     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00415-6     Document Type: Article

References (30)

1. William T, Jelip J, Menon J, et al. Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malar J 2014, 13:390.
2. Yusof R, Lau Y-L, Mahmud R, et al. High proportion of knowlesi malaria in recent malaria cases in Malaysia. Malar J 2014, 13:1-9.
3. Singh B, Daneshvar C Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013, 26:165-184.
4. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013, 12:8.
5. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008, 46:165-171.
6. Barber BE, William T, Grigg MJ A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013, 56:383-397.
7. Rajahram GS, Barber BE, William T, Menon J, Anstey NM, Yeo TW Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J 2012, 11:284.
8. Verdrager J Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. J Trop Med Hyg 1986, 89:277-289.
9. Price RN, Seidlein von L, Valecha N, Nosten F, Baird KJ, White NJ Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014, 14:982-991.
10. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010, 9:238.
11. Fatih FA, Staines HM, Siner A, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar J 2013, 12:425.
12. Douglas NM, Simpson JA, Phyo AP, et al. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis 2013, 208:801-812.
13. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, 10:673-681.
14. Guidelines for the treatment of malaria 2015, WHO, World Health Organization, Geneva. Third Edition.
15. Malaysian Ministry of Health. Management guidelines of malaria in Malaysia. Vector Borne Disease Sector, Disease Control Division, Ministry of Health, Malaysia, in Cooperation with Health Education Division, 2013.
16. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010, 10:405-416.
17. Grigg MJ, William T, Dhanaraj P, et al. A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial). BMJ Open 2014, 4:e006005.
18. Parasite clearance estimator WWARN, (accessed Dec 24, 2014). http://www.wwarn.org/tools-resources/toolkit/analyse/parasite-clearance-estimator-pce.
19. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity WHO, (accessed June 10, 2015). http://www.who.int/vmnis/indicators/haemoglobin.pdf.
20. William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011, 17:1248-1255.
21. Imwong M, Tanomsing N, Pukrittayakamee S, Day NPJ, White NJ, Snounou G Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P knowlesi. J Clin Microbiol 2009, 47:4173-4175.
22. Padley D, Moody AH, Chiodini PL, Saldanha J Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol 2003, 97:131-137.
23. McCarthy JS, Griffin PM, Sekuloski S, et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis 2013, 208:1688-1694.
24. Terkuile F, White NJ, Holloway P, Pasvol G, Krishna S Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993, 76:85-95.
25. Russell B, Chalfein F, Prasetyorini B, et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 2008, 52:1040-1045.
26. Berry A, Iriart X, Wilhelm N, et al. Imported Plasmodium knowlesi malaria in a French tourist returning from Thailand. Am J Trop Med Hyg 2011, 84:535-538.
27. Hoosen A, Shaw MTM Plasmodium knowlesi in a traveller returning to New Zealand. Travel Med Infect Dis 2011, 9:144-148.
28. Peatey CL, Skinner-Adams TS, Dixon MWA, McCarthy JS, Gardiner DL, Trenholme KR Effect of antimalarial drugs on Plasmodium falciparum gametocytes. J Infect Dis 2009, 200:1518-1521.
29. Chin W, Contacos PG, Collins WE, Jeter MH, Alpert E Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey. Am J Trop Med Hyg 1968, 17:355-358.
30. Phillips-Howard PA, Kuile Ter FO CNS adverse events associated with antimalarial agents. Fact or fiction?. Drug Saf 1995, 12:370-383.